Osiris Therapeutics announced completion of enrollment for its Phase 2 study of Prochymal (remestemcel-L) for the treatment of myocardial infarction. This study is a double-blind, placebo-controlled trial evaluating the safety and efficacy of Prochymal in conjunction with standard of care in improving heart function in patients who experienced their first heart attack. Efficacy endpoints determined from cardiac MRI include end systolic volume, LVEF and the ability of Prochymal to preserve functional heart tissue and limit scar formation following a myocardial infarction. In addition, functional and quality of life assessments will be performed.

Prochymal is an adult mesenchymal stem cell therapy. 

For more information call (443) 545-1800 or visit www.osiris.com.